Article
Oncology
Mohamad Moussa, Mohamad Abou Chakra, Wajih Saad, Athanasios Dellis, Athanasios Papatsoris
Summary: PET-CT is more accurate and sensitive than CT scan alone for preoperative LN staging in patients with bladder cancer, providing better diagnostic value for LN metastasis.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Gastroenterology & Hepatology
Tim Akhurst, Mithat Gonen, Raymond E. Baser, Lawrence H. Schwartz, Scott Tuorto, Lynn A. Brody, Anne Covey, Karen T. Brown, Steven M. Larson, Yuman Fong
Summary: The study compared the utility of FDG-PET with CT and CTAP for preoperative staging of hepatic colorectal metastases. FDG-PET had a significant impact on treatment decisions for nearly one-third of patients, mainly due to detection of extrahepatic disease. However, it was found to have lower sensitivity for hepatic sites, especially for small liver tumors.
HEPATOBILIARY SURGERY AND NUTRITION
(2022)
Article
Gastroenterology & Hepatology
Youpei Lin, Huanhuan Chong, Guohe Song, Chenhao Zhang, Liangqing Dong, Ling Aye, Fei Liang, Shuaixi Yang, Mengsu Zeng, Guangyu Ding, Shu Zhang, Jieyi Shi, Aiwu Ke, Xiaoying Wang, Jian Zhou, Jia Fan, Qiang Gao
Summary: F-18-FDG PET/CT is valuable for diagnosing regional lymph node and distant metastasis in intrahepatic cholangiocarcinoma (ICC) patients, leading to improved accuracy of preoperative staging and potential modification of treatment strategies. Patients undergoing PET/CT showed significantly longer overall survival compared to those without PET/CT.
HEPATOBILIARY SURGERY AND NUTRITION
(2021)
Article
Medicine, General & Internal
Eiko Nishioka, Masakatsu Tsurusaki, Ryohei Kozuki, Sung-Woon Im, Atsushi Kono, Kazuhiro Kitajima, Takamichi Murakami, Kazunari Ishii
Summary: The accuracy of tumor staging in intrahepatic cholangiocarcinoma (ICC) was examined using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET-CT). The study found that PET-CT had higher accuracy in diagnosing regional lymph node metastases compared to CT and MRI, while its accuracy in other indicators was similar to CT and MRI.
Article
Radiology, Nuclear Medicine & Medical Imaging
Virginia Liberini, Michael Messerli, Lars Husmann, Ken Kudura, Hannes Grunig, Alexander Maurer, Stephan Skawran, Erika Orita, Daniele A. Pizzuto, Desiree Deandreis, Reinhard Dummer, Joanna Mangana, Daniela Mihic-Probst, Niels Rupp, Martin W. Huellner
Summary: BSREM detects significantly more ITM than OSEM, with higher SUVmax, higher TBR, and less blurring. BSREM is particularly helpful in small and less avid lesions, which are more often missed with OSEM.
EUROPEAN RADIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kristine E. Fasmer, Ankush Gulati, Julie A. Dybvik, Kari S. Wagner-Larsen, Njal Lura, Oyvind Salvesen, David Forsse, Jone Trovik, Johanna M. A. Pijnenborg, Camilla Krakstad, Ingfrid S. Haldorsen
Summary: This study evaluated the diagnostic performance of four different preoperative imaging workups for predicting lymph node metastases in endometrial cancer. The results showed that selective use of [F-18]FDG-PET/CT in patients with high-risk MRI findings detected lymph node metastases better than MRI alone.
EUROPEAN RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kailin Qiao, Xueting Qin, Shuai Fu, Jiazhong Ren, Jing Jia, Xinying Hu, Yuanyuan Tao, Shuanghu Yuan, Yuchun Wei
Summary: The uptake of [F-18]AlF-NOTA-FAPI-04 and [F-18]FDG imaging tracers varies in malignant and inflammatory lung lesions, with lower uptake observed in inflammatory lesions. This difference in uptake can be valuable for distinguishing between malignancy and various inflammatory findings.
EUROPEAN RADIOLOGY
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Benjamin Koa, Austin J. Borja, Mahmoud Aly, Sayuri Padmanabhan, Joseph Tran, Vincent Zhang, Chaitanya Rojulpote, Sheila K. Pierson, Mark-Avery Tamakloe, Johnson S. Khor, Thomas J. Werner, David C. Fajgenbaum, Abass Alavi, Mona-Elisabeth Revheim
Summary: Castleman disease is a rare hematologic condition involving lymphadenopathy and clinical abnormalities, classified into UCD and MCD; MCD is further divided based on etiological driver; FDG-PET/CT plays an important role in differential diagnosis and monitoring treatment responses.
INSIGHTS INTO IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ieun Yoon, Jae Seok Bae, Jeongin Yoo, Dong Ho Lee, Se Hyung Kim
Summary: Studies suggest that compared to MDCT alone, MDCT combined with [F-18]FDG PET/MRI can improve the diagnostic accuracy for preoperative M staging and resectability in patients with recurrent gastric cancer, with a significant advantage in evaluating M staging.
EUROPEAN RADIOLOGY
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
K. S. M. van der Geest, G. Treglia, A. W. J. M. Glaudemans, E. Brouwer, F. Jamar, R. H. J. A. Slart, O. Gheysens
Summary: [18F]FDG-PET/CT scanning can effectively diagnose polymyalgia rheumatica by identifying significant uptake of FDG at specific anatomic sites. The technique shows promise as an important diagnostic tool for patients with suspected PMR, but standardized interpretation criteria and procedural recommendations are necessary for its use.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Oncology
Sungmin Woo, Anton S. Becker, Richard K. G. Do, Heiko Schoder, Hedvig Hricak, H. Alberto Vargas
Summary: FDG-PET or PET/CT had a meaningful impact on the management of patients with CUP, with approximately a third of patients having their management changed as a result, mainly due to detection of the primary site. This finding was consistent across numerous subgroups.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Dan Shao, Qiang Gao, You Cheng, Dong-Yang Du, Si-Yun Wang, Shu-Xia Wang
Summary: The study demonstrates that F-18-FDG PET/CT can predict the survival of patients with primary tracheal malignant tumors. Patients with higher metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on PET/CT scans, squamous cell carcinoma, and non-E1 surgeries are more likely to have reduced overall survival.
KOREAN JOURNAL OF RADIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wan-Ming Chen, Mingchih Chen, Jeng-Guan Hsu, Tian-Shyug Lee, Ben-Chang Shia, Szu-Yuan Wu
Summary: The use of preoperative PET/CT is associated with a lower risk of death in patients with resectable stage IIIA-IIIB non-small cell lung cancer, but it does not improve survival rates in patients with stage I-II cancer.
Article
Radiology, Nuclear Medicine & Medical Imaging
Weishen Wang, Siwen Wang, Xinyun Huang, Hongping Meng, Yu Jiang, Biao Li, Kemin Chen, Baiyong Shen, Xiaozhu Lin
Summary: This study found that hybrid 18F-FDG PET/MR imaging has high accuracy in the preoperative assessment of pancreatic cancer, diagnosing advanced stages and influencing treatment decisions for patients.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
(2022)
Article
Oncology
Kuo-Chen Wu, Shang-Wen Chen, Te-Chun Hsieh, Kuo-Yang Yen, Kin-Man Law, Yu-Chieh Kuo, Ruey-Feng Chang, Chia-Hung Kao
Summary: A new artificial intelligence model utilizing baseline 18F[F]DG-PET/CT images was introduced to predict responses to neoadjuvant chemoradiotherapy in rectal cancer patients, showing high predictive performance in the training cohort with sensitivity, specificity, and accuracy of 98.3%, 96.5%, and 97.5% respectively. The model's predictive value needs further external validation.
Article
Oncology
Fara Braso-Maristany, Laia Pare, Nuria Chic, Olga Martinez-Saez, Tomas Pascual, Meritxell Mallafre-Larrosa, Francesco Schettini, Blanca Gonzalez-Farre, Esther Sanfeliu, Debora Martinez, Patricia Galvan, Esther Barnadas, Belinda Salinas, Pablo Tolosa, Eva Ciruelos, Esther Carcelero, Cecilia Guillen, Barbara Adamo, Reinaldo Moreno, Maria Vidal, Montserrat Munoz, Aleix Prat
Summary: The study evaluated gene expression in 184 metastatic samples across 11 organs in advanced breast cancer. While relevant tumor biology can be captured in metastatic tissues across various organ sites, unique biological features according to organ site were also identified.
MOLECULAR ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ariel Glickman, Pilar Paredes, Nuria Carreras-Dieguez, Aida Ninerola-Baizan, Lydia Gaba, Jaume Pahisa, Pere Fuste, Marta Del Pino, Berta Diaz-Feijoo, Eduardo Gonzalez-Bosquet, Nuria Agusti, Nuria Sanchez-Izquierdo, David Fuster, Andres Perissinotti, Inmaculada Romero, Esther Fernandez-Galan, Josep Lluis Carrasco, Blanca Gil-Ibanez, Aureli Torne
Summary: Accurate assessment of disease extent is crucial for selecting the best primary treatment for advanced epithelial ovarian cancer patients. Imaging techniques and tumour markers can help estimate tumour burden non-invasively, with 2-[F-18]FDG PET/CT providing a comprehensive evaluation of the disease. HE4 performs better than CA125 in predicting metabolic tumour burden, and PET/CT volumetric parameters are valuable tools for assessing tumour load in clinical practice.
EUROPEAN RADIOLOGY
(2022)
Editorial Material
Oncology
Nuria Agusti, Pilar Paredes, Sergi Vidal-Sicart, Ariel Glickman, Aureli Torne, Berta Diaz-Feijoo
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Oncology
Joan Carles, Teresa Alonso-Gordoa, Begona Mellado, Maria J. Mendez-Vidal, Sergio Vazquez, Aranzazu Gonzalez-del-Alba, Josep M. Piulats, Pablo Borrega, Enrique Gallardo, Rafael Morales-Barrera, Pilar Paredes, Oscar Reig, Carmen Garcias de Espana, Ricardo Collado, Teresa Bonfill, Cristina Suarez, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Garde
Summary: In this study of 52 patients with metastatic castration-resistant prostate cancer and asymptomatic bone metastases, treatment with Ra-223 was found to have longer radiographic progression-free survival (rPFS) and overall survival in patients with AR-V7(-) expression. Ra-223 demonstrated an acceptable safety profile for the treatment of these patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Guillermo Villacampa, Claudette Falato, Laia Pare, Cristina Hernando, Miriam Arumi, Cristina Saura, Guadalupe Gomez, Montserrat Munoz, Miguel Gil-Gil, Yann Izarzugaza, Neus Ferrer, Josu Najera-Zuloaga, Alvaro Montano, Eva Ciruelos, Santiago Gonzalez-Santiago, Patricia Villagrasa, Joaquin Gavila, Aleix Prat, Tomas Pascual
Summary: This study reports the HRQoL analysis results of the CORAL-LEEN trial, comparing neoadjuvant ribociclib plus letrozole (R + L) with chemotherapy in patients with PAM50 luminal B early breast cancer. The results show that patients receiving R + L treatment had better HRQoL outcomes, including global health status and various functional and symptom scales, compared to chemotherapy.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
P. Paredes, B. Diaz-Feijoo, E. Aguilar Galan, M. de Matias Martinez, S. Fuertes Cabero
Summary: This paper presents a multidisciplinary view on the controversial issues surrounding the sentinel lymph node procedure in endometrial cancer, focusing on the pros and cons of different tracers including radiotracers, hybrid tracers, and indocyanine green.
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
(2022)
Article
Medical Informatics
Santiago Frid, Maria Angeles Fuentes Exposito, Inmaculada Grau-Corral, Clara Amat-Fernandez, Montserrat Munoz Mateu, Xavier Pastor Duran, Raimundo Lozano-Rubi
Summary: This study developed a methodology based on the dual-model paradigm to facilitate communication of clinical information between a patient mobile app and an institutional clinical repository. By utilizing EN/ISO 13606 standardized archetypes and ontologies, the study achieved clinical information reuse and extended the knowledge representation of the clinical repository.
JMIR MEDICAL INFORMATICS
(2022)
Review
Oncology
Marianna Sirico, Alessandra Virga, Benedetta Conte, Milena Urbini, Paola Ulivi, Caterina Gianni, Filippo Merloni, Michela Palleschi, Marco Gasperoni, Annalisa Curcio, Debjani Saha, Giuseppe Buono, Montserrat Munoz, Ugo De Giorgi, Francesco Schettini
Summary: Neoadjuvant endocrine treatment (NET) shows satisfactory efficacy in breast cancer patients who are hormone receptor-positive (HR+)/HER2-negative, achieving high rates of breast conservative surgery and converting inoperable patients to operable status with less toxicity compared to neoadjuvant chemotherapy (NACT). However, challenges such as heterogeneous patient response and the duration needed for a clinical response limit the widespread use of NET. Recent advancements in biomarker research, including the PEPI score, Ki67, and genomic assays, have increased interest in NET. This review aims to provide an overview of the current state and future perspectives of NET, as well as the potential integration of molecular biomarkers for patient selection and treatment duration.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Fara Braso-Maristany, Gaia Griguolo, Nuria Chic, Tomas Pascual, Laia Pare, Julia Maues, Patricia Galvan, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martinez-Saez, Mercedes Marin-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Munoz, Esther Sanfeliu, Blanca Gonzalez, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, PierFranco Conte, Aleix Prat, Valentina Guarneri
Summary: This study evaluated the association between ERBB2 mRNA expression levels and response and survival following T-DM1 treatment. The results showed that ERBB2 mRNA expression levels were associated with better survival and treatment response.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Respiratory System
Ivan Vollmer, Alfredo Paez-Carpio, David Sanchez-Lorente, Marc Boada, Daniel Martinez, Marcelo Sanchez, Nuria Sanchez-Izquierdo, Marta Tormo-Ratera, Jordi Ribera-Perianes, Sergi Vidal-Sicart, Enrique Carrero-Cardenal, Pilar Paredes
Summary: This study compared preoperative lung nodule localization using hookwire and radiotracer injection (ROLL). The ROLL technique was found to be safer and tended to result in smaller resection samples compared to hookwire localization.
JOURNAL OF THORACIC DISEASE
(2022)
Review
Oncology
Miguel Martin, Eva Carrasco, Alvaro Rodriguez-Lescure, Raquel Andres, Sonia Servitja, Antonio Anton, Manuel Ruiz-Borrego, Begona Bermejo, Angel Guerrero, Manuel Ramos, Ana Santaballa, Montserrat Munoz, Josefina Cruz, Sara Lopez-Tarruella, Jose I. I. Chacon, Isabel Alvarez, Purificacion Martinez, Juan J. Miralles, Oscar Polonio, Carlos Jara, David Aguiar-Bujanda
Summary: This study analyzed the long-term outcomes of patients similar to the monarchE trial to evaluate the potential benefit of abemaciclib. The results indicated the need for new therapies to improve survival rates for these patients.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Angel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Munoz-Mateu, Begon Bermejo, Mireia Margeli Vila, Antonio Anton, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalia Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martin
Summary: In patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer, non-luminal subtype and high CCNE1 expression are associated with resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and poor response to treatment. Furthermore, high levels of the Polo-like kinase 1 (PLK1) mRNA indicate resistance to palbociclib, suggesting that PLK1 may play a role in CDK4/6i resistance. These findings highlight the need for validation of these biomarkers and the exploration of PLK1 as a therapeutic target.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Aleix Prat, Fara Braso-Maristany, Olga Martinez-Saez, Esther Sanfeliu, Youli Xia, Meritxell Bellet, Patricia Galvan, Debora Martinez, Tomas Pascual, Mercedes Marin-Aguilera, Anna Rodriguez, Nuria Chic, Barbara Adamo, Laia Pare, Maria Vidal, Mireia Margeli, Ester Ballana, Marina Gomez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sanchez-Bayona, Anna Sunol, Cristina Saura, Eva Ciruelos, Pablo Tolosa, Montserrat Munoz, Blanca Gonzalez-Farre, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Ana Vivancos
Summary: This study uses shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in metastatic breast cancer patients. Machine learning multi-gene signatures obtained from ctDNA can identify complex biological features similar to those obtained from direct tumor tissue DNA or RNA profiling.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Ruben Olivera-Salguero, Elia Segui, Juan Miguel Cejalvo, Mafalda Oliveira, Pablo Tolosa, Maria Vidal, Marcos Malumbres, Joaquin Gavila, Cristina Saura, Sonia Pernas, Rafael Lopez, Mireia Margeli, Judith Balmana, Montserrat Munoz, Isabel Blancas, Valentina Boni, Eva Ciruelos, Elena Galve, Antonia Perello, Rodrigo Sanchez-Bayona, Susana de la Cruz, Miguel de la Hoya, Patricia Galvan, Esther Sanfeliu, Blanca Gonzalez-Farre, Valeria Sirenko, Aura Blanch-Torras, Jordi Canes, Helena Masanas, Rosa Olmos, Margarita Forns, Aleix Prat, Ana Casas, Tomas Pascual
Summary: This study aims to promote active patient participation in the management of metastatic breast cancer (mBC) through a digital tool, providing NGS testing and medical interpretation and recommendations from a multidisciplinary molecular advisory board (MAB), to overcome the challenges of limited access and high cost of NGS in clinical practice.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Francesco Schettini, Elia Segui, Benedetta Conte, Esther Sanfeliu, Blanca Gonzalez-Farre, Pedro Jares, Sergi Vidal-Sicart, Sergi Ganau, Isaac Cebrecos, Fara Braso-Maristany, Montserrat Munoz, Aleix Prat, Maria Vidal
Summary: This clinical case confirms the presence of non-luminal subtypes in HR+/HER2-neg disease and highlights the potential therapeutic implications in the metastatic setting. It also questions the recommendation of upfront chemotherapy in the case of a visceral crisis in the era of CDKi-based regimens. Further evaluation in prospective and larger studies is needed.
FRONTIERS IN ONCOLOGY
(2022)